<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02757872</url>
  </required_header>
  <id_info>
    <org_study_id>2015P002330/BWH</org_study_id>
    <secondary_id>R01DK102952</secondary_id>
    <nct_id>NCT02757872</nct_id>
  </id_info>
  <brief_title>Effects of Vitamin D and Fish Oil on the Kidney in Hypertensives</brief_title>
  <official_title>Effects of Vitamin D and Fish Oil on the Kidney in Hypertensives</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albert Einstein College of Medicine, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Albert Einstein College of Medicine, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The VITamin D and OmegA-3 TriaL (VITAL; NCT 01169259) is an ongoing randomized clinical trial
      in 25,875 US men and women investigating whether taking dietary supplements of vitamin D3
      (2000 IU) or omega-3 fatty acids (Omacor (R) fish oil, 1 gram) reduces the risk of developing
      cancer, heart disease, and stroke in people who do not have a prior history of these
      illnesses. The VITAL Kidney Function in Hypertension ancillary study will evaluate the
      effects of vitamin D or omega-3 fatty acids on kidney function among participants with
      baseline hypertension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This ancillary study to the VITamin D and OmegA-3 TriaL (VITAL) will test whether vitamin D3,
      omega-3 fatty acids, or both prevent the development and progression of kidney disease in
      participants with hypertension. Persons with hypertension are at high risk of kidney disease.

      Vitamin D and omega-3 fatty acids are promising interventions for kidney disease prevention
      and treatment, based on results of animal-experimental models and early human studies.
      Because these interventions are relatively safe, inexpensive, and widely available, they may
      offer opportunity to substantially reduce the burden of kidney disease in large populations.
      This VITAL ancillary study will test whether vitamin D3 and/or omega-3 fatty acids prevent
      loss of glomerular filtration rate, over 4 years of therapy.

      In VITAL, 25,875 participants have been randomly assigned in a 2x2 factorial design to
      vitamin D3 (cholecalciferol) 2000 IU daily versus placebo, and to eicosapentaenoic acid 465
      mg plus docosahexaenoic acid 375 mg daily versus placebo, and followed for a mean of 5 years
      to assess effects on cardiovascular disease and cancer events. This ancillary study will
      identify and recruit a sub-cohort of VITAL participants with hypertension at baseline and
      ascertain effects of study interventions on glomerular filtration rate in this group. Blood
      samples will be collected at year 4 simultaneously for measurement of estimated glomerular
      filtration rate (using serum creatinine and cystatin C) and other relevant biomarkers. This
      VITAL ancillary study is designed to determine whether vitamin D3 and/or omega-3 fatty acids
      have causal and clinically relevant effects on the development and progression of kidney
      disease in hypertensives.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in estimated glomerular filtration rate</measure>
    <time_frame>4 years</time_frame>
    <description>Serum creatinine and cystatin C measurement pre-randomization and year 4</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence of Albuminuria</measure>
    <time_frame>4 years post-randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">2612</enrollment>
  <condition>Hypertension</condition>
  <condition>Kidney Diseases</condition>
  <arm_group>
    <arm_group_label>Vitamin D and fish oil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dietary Supplement: Vitamin D Vitamin D3 (cholecalciferol), 2000 IU per day. Drug: Omega-3 fatty acids (fish oil) Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D and fish oil placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dietary Supplement: Vitamin D Vitamin D3 (cholecalciferol), 2000 IU per day. Dietary Supplement: Fish oil placebo Fish oil placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D placebo and fish oil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: Omega-3 fatty acids (fish oil) Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
Dietary Supplement: Vitamin D placebo Vitamin D3 placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D placebo and fish oil placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dietary Supplement: Vitamin D placebo Vitamin D3 placebo Dietary Supplement: Fish oil placebo Fish oil placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>Vitamin D3 (cholecalciferol), 2000 IU per day</description>
    <arm_group_label>Vitamin D and fish oil</arm_group_label>
    <arm_group_label>Vitamin D and fish oil placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omega-3 Fatty acids</intervention_name>
    <description>Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])</description>
    <arm_group_label>Vitamin D and fish oil</arm_group_label>
    <arm_group_label>Vitamin D placebo and fish oil</arm_group_label>
    <other_name>Fish oil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3 placebo</intervention_name>
    <description>Vitamin D3 placebo</description>
    <arm_group_label>Vitamin D placebo and fish oil</arm_group_label>
    <arm_group_label>Vitamin D placebo and fish oil placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fish oil placebo</intervention_name>
    <description>Fish oil placebo</description>
    <arm_group_label>Vitamin D and fish oil placebo</arm_group_label>
    <arm_group_label>Vitamin D placebo and fish oil placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants in VITAL (NCT 01169259) with a self-reported physician diagnosis of
             hypertension are eligible to participate in this ancillary study

        Exclusion Criteria:

          -  Diagnosis of diabetes mellitus
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michal L Melamed, MD, MHS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Albert Einstein College of Medicine, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2016</study_first_submitted>
  <study_first_submitted_qc>April 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2016</study_first_posted>
  <last_update_submitted>April 19, 2018</last_update_submitted>
  <last_update_submitted_qc>April 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Albert Einstein College of Medicine, Inc.</investigator_affiliation>
    <investigator_full_name>Michal L. Melamed</investigator_full_name>
    <investigator_title>Associate Professor of Medicine and Epidemiology &amp;Population Health</investigator_title>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Kidney Diseases</keyword>
  <keyword>Vitamin D</keyword>
  <keyword>Omega 3 fatty acids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

